EDGAR Filing Documents for 0001640334-23-001358

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001640334-23-001358

Filing Date

2023-07-25

Accepted

2023-07-25 16:02:30

Documents

Period of Report

2023-07-25

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 6-K	nymox_6k.htm	6-K	9357
2	EX-99.1	nymox_ex991.htm	EX-99.1	2155
3		nymox_ex991img1.jpg	GRAPHIC	321085
4		nymox_ex991img2.jpg	GRAPHIC	389731
5		nymox_ex991img3.jpg	GRAPHIC	158944
	Complete submission text file	0001640334-23-001358.txt		1210887

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 231108542
SIC: 2835 In Vitro & In Vivo Diagnostic Substances